BMS-554417

structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Ovarian Neoplasms (Ovarian Cancer) 09/01/2008 - "Further studies indicated treatment of OV202 ovarian cancer cells with BMS-554417 increased phosphorylation of HER-2. " 09/01/2008 - "We have reported previously the activity of the insulin-like growth factor-I (IGF-IR)/insulin receptor (InsR) inhibitor, BMS-554417, in breast and ovarian cancer cell lines. "
2.	Neoplasms (Cancer) 01/01/2006 - "BMS-554417 was orally bioavailable and significantly inhibited the growth of IGF1R-Sal tumor xenografts in vivo. " 01/01/2006 - "Here, we show that BMS-554417, a novel small molecule developed as an inhibitor of IGF-IR, inhibits IGF-IR and insulin receptor kinase activity and proliferation in vitro, and reduces tumor xenograft size in vivo. "

1.	Insulin Receptor
2.	Phosphotransferases (Kinase)
3.	Insulin-Like Growth Factor I (IGF-1)